BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
5/24/2022 12:41:49 PM | Browse: 398 | Download: 857
 |
Received |
|
2021-04-28 08:21 |
|
Peer-Review Started |
|
2021-04-28 08:23 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2021-06-07 00:56 |
|
Revised |
|
2021-06-24 01:33 |
|
Second Decision |
|
2022-05-06 03:05 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2022-05-07 00:46 |
|
Articles in Press |
|
2022-05-07 00:46 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2022-05-13 08:32 |
|
Publish the Manuscript Online |
|
2022-05-24 12:41 |
| ISSN |
2218-4333 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Minireviews |
| Article Title |
Neoadjuvant treatment in non-small cell lung cancer: New perspectives with the incorporation of immunotherapy
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Carlos Aguado, Luis Chara, Mónica Antoñanzas, Jose Maria Matilla Gonzalez, Unai Jiménez, Raul Hernanz, Xabier Mielgo-Rubio, Juan Carlos Trujillo-Reyes and Felipe Couñago |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Carlos Aguado, MD, Consultant Physician-Scientist, Medical Oncology, Hospital Clínico Universitario San Carlos, Calle del Prof Martín Lagos, s/n, 28040 Madrid, Madrid 28040, Spain. carlos.aguado84@gmail.com |
| Key Words |
Non-small cell lung cancer; Neoadjuvant; Immune checkpoint inhibitors; Immunotherapy; Anti-PD1; Anti-PD-L1; Complete pathological response |
| Core Tip |
Studies evaluating neoadjuvant immunotherapy in non-small cell lung cancer have reported extraordinary pathological response rates without any increase in postoperative complications. However, before immunotherapy is implemented in routine clinical practice, several issues still need to be resolved. This review analyses the current evidence for immunotherapy from a multidisciplinary perspective and discusses current and future controversies. |
| Publish Date |
2022-05-24 12:41 |
| Citation |
Aguado C, Chara L, Antoñanzas M, Matilla Gonzalez JM, Jiménez U, Hernanz R, Mielgo-Rubio X, Trujillo-Reyes JC, Couñago F. Neoadjuvant treatment in non-small cell lung cancer: New perspectives with the incorporation of immunotherapy. World J Clin Oncol 2022; 13(5): 314-322 |
| URL |
https://www.wjgnet.com/2218-4333/full/v13/i5/314.htm |
| DOI |
https://dx.doi.org/10.5306/wjco.v13.i5.314 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
